Autogenous Vaccine Market Expected to Reach US$ 246.8 Million by 2034: Fact.MR Report
Increasingly Stringent Regulations Governing Animal Healthcare to Control Spread of Diseases Pushing Demand for Autogenous Vaccines
Rockville , Feb. 16, 2024 (GLOBE NEWSWIRE) -- The global autogenous vaccine market is estimated at a valuation of US$ 144.8 million in 2024, according to a new study published by Fact.MR, a market research and competitive intelligence provider. The market is projected to reach US$ 246.8 million by the end of 2034.*Get Free Sample Copy of This Report:*
*https://www.factmr.com/connectus/sample?flag=S&rep_id=9730*
Increasing livestock culture and a growing number of livestock farms along with rising incidences of diseases in aquaculture and poultry farms are projected to contribute to the autogenous vaccine demand. In addition, governments and organizations are implementing regulations and programs to control the spread of animal diseases, which are further contributing to the growing demand for autogenous vaccines.
Rabies, swine flu, brucellosis, and bird flu are a few of the diseases that affect animals in farms. They can be prevented with the adoption of custom vaccines to treat that specific flock's disease and make their immune systems passively stronger for that disease. Further, growing health consciousness among livestock owners along with rising expenditure on their healthcare is forecasted to contribute to market growth going forward.
Manufacturers of animal healthcare solutions, especially poultry, are dependent on their direct sales staff to establish connections with respective customers. More market companies are using this strategy to enhance product awareness, provide training & assistance, and establish treatment protocol.
*Report Attribute* *Details*
Value Projection (2034) US$ 246.8 Million
Growth Rate (2024-2034) 5.5% CAGR
No. of pages 170 Pages
No. of Tables 25 Tables
No. of Figures 132 Figures
*Key Takeaways from Market Study *
· The global autogenous vaccine market is estimated at US$ 144.8 million in 2024.
· Worldwide sales of autogenous vaccines are projected to reach US$ 246.8 million by the end of 2034.
· The market is forecasted to expand at 5.5% CAGR from 2024 to 2034.
· The United States is projected to account for 93.6% share of the North American market by 2034.
· Bacterial strains are forecasted to hold 71% share of global revenue by 2034.
· The market in Mexico is projected to expand at a CAGR of 4.6% from 2024 to 2034.
*“Increasing pet adoption rate, reduction in the use of antibiotics, and improvement in animal safety education are forecasted to support demand for autogenous vaccines,” *says a Fact.MR analyst.
*Key Companies Profiled in This Report*
· Newport Laboratories, Inc.
· Ceva
· Elanco Animal Health
· ACE Laboratory Services
· AniCon Labor GmbH
· Huvepharma, Inc.
· Cambridge Technologies
· Dyntec s. r. o.
· Vaxxinova
· Hygieia Biological Laboratories
· Sanphar
· Addison Biological Laboratory
· Kennebec River Biosciences
· Barramundi Asia Pte Ltd.
*High Awareness Among Farmers about Livestock Diseases and Associated Preventive Measures in United States*
Demand for autogenous vaccines in the United States is forecasted to increase at a 4.9% CAGR and reach a value of US$ 80 million by 2034-end. Increasing awareness among more farmers related to livestock diseases along with their preventive measures is projected to contribute to the growing demand for autogenous vaccines. The animal health sector and researchers are involved in the development and improvement of suitable diagnostic reagents, effective vaccines, and specialized diagnostic assays, which is leading to the production of customized vaccines in the United States.
*Get Customization on this Report for Specific Research Solutions:*
*https://www.factmr.com/connectus/sample?flag=RC&rep_id=9730*
*More Valuable Insights* *on Offer *
Fact.MR, in its new offering, presents an unbiased analysis of the autogenous vaccine market, presenting historical demand data for 2018 to 2023 and forecast statistics for 2024 to 2034.
The study divulges essential insights into the market based on product (bacterial strain, virus strain) and end user (veterinary research institutes, livestock farming companies, veterinary clinics & hospitals), across six major regions of the world (North America, Europe, East Asia, Latin America, South Asia & Oceania, and MEA).
*Explore More Related Studies Published by Fact.MR Research:*
*Vaccine Management Solution Market:* The global vaccine management solution market has reached a valuation of *US$ 233 million* in 2022 and is expected to progress at a *CAGR of 11.9%* to reach *US$ 721 million* by the end of 2032.
*Respiratory Virus Vaccines Market:* The global respiratory virus vaccines market size is valued at US$ 8.69 billion in 2023 and is predicted to reach US$ 18.6 billion by 2033-end, expanding at a CAGR of 7.9% over the forecast period (2023 to 2033).
*Vaccine Adjuvants Market:* The market is expected to reach a valuation of US$ 6.8 Billion by 2033.
*About Fact.MR**:*
Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.
*Contact: *
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
*Sales Team: *sales@factmr.com
*Follow Us: *LinkedIn | Twitter | Blog